Innoviva Inc (INVA) stock is lower by 2.48% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With INVA Stock Today?
Innoviva Inc (INVA) stock is trading at $11.41 as of 10:30 AM on Friday, Apr 30, a loss of -$0.26, or -2.23% from the previous closing price of $11.67. The stock has traded between $11.15 and $11.67 so far today. Volume today is 426,131 compared to average volume of 512,936.
To screen for more stocks like Innoviva Inc click here.
More About Innoviva Inc
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Click Here to get the full Stock Score Report on Innoviva Inc (INVA) Stock.
